LENSAR (LNSR)


Market Price (11/16/2026): $5.25 | Market Cap: $64.5 MilSector: Health Care | Industry: Life Sciences Tools & Services

LENSAR (LNSR)


Market Price (11/16/2026): $5.25
Market Cap: $64.5 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 54%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 49%

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -17%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, and Targeted Therapies.

Weak multi-year price returns
2Y Excs Rtn is -59%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -2.0 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3.3%

Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -1.3%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -7.7%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7.9%

Key risks
LNSR key risks include [1] its heavy dependence on the commercial success of its ALLY system to achieve profitability after a history of losses and [2] significant uncertainties and costs stemming from its pending acquisition by Alcon, Show more.

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 54%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 49%
1 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -17%
2 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, and Targeted Therapies.
3 Weak multi-year price returns
2Y Excs Rtn is -59%
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -2.0 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3.3%
5 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -1.3%
6 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -7.7%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7.9%
7 Key risks
LNSR key risks include [1] its heavy dependence on the commercial success of its ALLY system to achieve profitability after a history of losses and [2] significant uncertainties and costs stemming from its pending acquisition by Alcon, Show more.

LNSR in ETFs

Weight = LNSR's share of each fund

VTI0.00%
DFAS0.00%
DFAC0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/13/2026

Nov 13: up 6.4% in one day (S&P 500 down 0.4%)
This gain came without company news. The S&P 500 fell significantly that day.

Down 50.4% from its Aug 24 high to Nov 11, up 9.2% since (S&P 500 down 0.2%)
The sustained decline occurred without company news for most of the period, though the market showed broad concerns on November 5. The largest single-day drops occurred on November 5, when the S&P 500 also fell significantly amid reports of market concerns, and on November 10 following third quarter results.

Nov 10: down 15.4% on its earnings report (S&P 500 down 0.4%)
The company's third quarter 2026 financial results reported a decline in revenue, net income, and diluted EPS compared to a year earlier. This decline occurred despite 10 ALLY System placements and led to a significant stock drop.

Show more
Prices as of 11/13/2026

Nov 13: up 6.4% in one day (S&P 500 down 0.4%)
This gain came without company news. The S&P 500 fell significantly that day.

Down 50.4% from its Aug 24 high to Nov 11, up 9.2% since (S&P 500 down 0.2%)
The sustained decline occurred without company news for most of the period, though the market showed broad concerns on November 5. The largest single-day drops occurred on November 5, when the S&P 500 also fell significantly amid reports of market concerns, and on November 10 following third quarter results.

Nov 10: down 15.4% on its earnings report (S&P 500 down 0.4%)
The company's third quarter 2026 financial results reported a decline in revenue, net income, and diluted EPS compared to a year earlier. This decline occurred despite 10 ALLY System placements and led to a significant stock drop.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -0.2% change in LNSR stock from 7/31/2026 to 11/15/2026 was primarily driven by a -11.2% change in the company's P/E Multiple.
(LTM values as of)731202611152026Change
Stock Price ($)5.015.00-0.2%
Change Contribution By: 
Total Revenues ($ Mil)58604.1%
Net Income Margin (%)50.9%56.1%10.1%
P/E Multiple2.11.8-11.2%
Shares Outstanding (Mil)1212-1.9%
Cumulative Contribution-0.2%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/15/2026
ReturnCorrelation
LNSR-0.2% 
Market (SPY)1.2%24.7%
Sector (XLV)16.6%18.9%

Fundamental Drivers

The -4.4% change in LNSR stock from 4/30/2026 to 11/15/2026 was primarily driven by a -4.5% change in the company's P/S Multiple.
(LTM values as of)430202611152026Change
Stock Price ($)5.235.00-4.4%
Change Contribution By: 
Total Revenues ($ Mil)58602.8%
P/S Multiple1.11.0-4.5%
Shares Outstanding (Mil)1212-2.6%
Cumulative Contribution-4.4%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/15/2026
ReturnCorrelation
LNSR-4.4% 
Market (SPY)5.5%15.7%
Sector (XLV)30.4%16.4%

Fundamental Drivers

The -59.3% change in LNSR stock from 10/31/2025 to 11/15/2026 was primarily driven by a -59.0% change in the company's P/S Multiple.
(LTM values as of)1031202511152026Change
Stock Price ($)12.305.00-59.3%
Change Contribution By: 
Total Revenues ($ Mil)58602.9%
P/S Multiple2.51.0-59.0%
Shares Outstanding (Mil)1212-3.7%
Cumulative Contribution-59.3%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/15/2026
ReturnCorrelation
LNSR-59.3% 
Market (SPY)11.8%13.8%
Sector (XLV)33.1%15.4%

Fundamental Drivers

The 132.6% change in LNSR stock from 10/31/2023 to 11/15/2026 was primarily driven by a 69.6% change in the company's P/S Multiple.
(LTM values as of)1031202311152026Change
Stock Price ($)2.155.00132.6%
Change Contribution By: 
Total Revenues ($ Mil)386057.1%
P/S Multiple0.61.069.6%
Shares Outstanding (Mil)1112-12.7%
Cumulative Contribution132.6%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/15/2026
ReturnCorrelation
LNSR132.6% 
Market (SPY)87.0%12.2%
Sector (XLV)59.4%12.6%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
LNSR Return-17%-51%19%155%30%-57%-31%
Peers Return11%-8%1%1%21%32%65%
S&P 500 Return27%-19%24%23%16%11%103%

Monthly Win Rates [3]
LNSR Win Rate33%17%67%58%42%27% 
Peers Win Rate58%54%50%46%67%59% 
S&P 500 Win Rate75%42%67%75%67%45% 

Max Drawdowns [4]
LNSR Max Drawdown-38%-67%-55%-40%-43%-64% 
Peers Max Drawdown-12%-13%-23%-18%-26%-16% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: JNJ, BLCO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/13/2026 (YTD)

How Low Can It Go

EventLNSRS&P 500
2025 US Tariff Shock
  % Loss-11.1%-18.8%
  % Gain to Breakeven12.5%23.1%
  Time to Breakeven6 days79 days
2024 Yen Carry Trade Unwind
  % Loss-12.3%-7.8%
  % Gain to Breakeven14.0%8.5%
  Time to Breakeven15 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-38.3%-9.5%
  % Gain to Breakeven62.2%10.5%
  Time to Breakeven48 days24 days
2023 SVB Regional Banking Crisis
  % Loss-28.0%-6.7%
  % Gain to Breakeven38.8%7.1%
  Time to Breakeven62 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-19.0%-24.5%
  % Gain to Breakeven23.5%32.4%
  Time to Breakeven12 days427 days

Compare to JNJ, BLCO

In The Past

LENSAR's stock fell -11.1% during the 2025 US Tariff Shock. Such a loss loss requires a 12.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventLNSRS&P 500
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-38.3%-9.5%
  % Gain to Breakeven62.2%10.5%
  Time to Breakeven48 days24 days
2023 SVB Regional Banking Crisis
  % Loss-28.0%-6.7%
  % Gain to Breakeven38.8%7.1%
  Time to Breakeven62 days31 days

Compare to JNJ, BLCO

In The Past

LENSAR's stock fell -11.1% during the 2025 US Tariff Shock. Such a loss loss requires a 12.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About LENSAR (LNSR)

```html

LENSAR, Inc. (LNSR) is a commercial-stage medical device company focused on the field of ophthalmology. The company specializes in developing, manufacturing, and marketing an advanced femtosecond laser system. This system is primarily utilized for two critical ophthalmic procedures: the treatment of cataracts and the precise management of corneal astigmatism, whether it is present before surgery or induced during a surgical procedure.

The company's flagship product is the LENSAR Laser System. This innovative system incorporates a suite of proprietary technologies designed to enhance surgical precision and outcomes. Key functionalities include advanced imaging capabilities, comprehensive procedure planning tools, design assistance for customized treatments, and high-precision laser delivery. These features are intended to significantly aid ophthalmic surgeons in achieving superior visual results, improving procedural efficiency, and ensuring reproducibility in patient care.

LENSAR's main customers are ophthalmic surgeons and the medical institutions, such as hospitals and specialized eye clinics, where these sophisticated laser-assisted procedures are performed. The company operates within the global ophthalmology market, addressing the significant demand for advanced solutions to treat prevalent vision-impairing conditions like cataracts and astigmatism.

```

AI Analysis | Feedback

  • Intuitive Surgical for ophthalmology: LENSAR provides advanced, high-precision laser systems to assist surgeons in eye procedures, similar to how Intuitive Surgical's robotic systems aid complex surgeries.
  • Stryker for ophthalmic laser systems: LENSAR offers specialized, high-tech laser equipment for eye surgery, akin to how Stryker provides innovative surgical instruments and implants for other medical fields.

AI Analysis | Feedback

  • LENSAR Laser System: A femtosecond laser system designed for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism.

AI Analysis | Feedback

LENSAR (LNSR) sells its LENSAR Laser System primarily to other companies in the healthcare sector, rather than directly to individuals.

Due to the nature of their business, LENSAR does not publicly disclose specific named "major customers" (individual hospitals, clinics, or distributors) that account for a significant portion of their revenue. Instead, their customer base consists of a broad network of healthcare providers and distributors. The company's customer categories, representing the types of businesses they sell to, are:

  • Ophthalmic Surgeons and Ophthalmology Practices: In the United States, LENSAR sells its systems directly to ophthalmic surgeons and their private practices or clinics. These are businesses that perform cataract surgery and and manage corneal astigmatism.
  • Ambulatory Surgical Centers (ASCs): LENSAR also sells its systems directly to Ambulatory Surgical Centers in the United States. ASCs are outpatient facilities where surgical procedures, including cataract surgery, are performed.
  • Third-Party Distributors: Outside the United States, LENSAR relies on a network of third-party distributors. These distributors are companies that purchase the LENSAR Laser System and related consumables and then resell them to local ophthalmic surgeons, clinics, and hospitals in their respective regions.

AI Analysis | Feedback

null

AI Analysis | Feedback

Nicholas T. Curtis Chief Executive Officer and Director

Nicholas T. Curtis has served as LENSAR's Chief Executive Officer and a member of its board of directors since February 2012, following his role as Chief Commercial Officer from August 2010. With over 35 years of experience in the ophthalmic industry, Mr. Curtis previously held senior positions, including Vice President of Sales and Chief Commercial Officer at WaveTec Vision Systems, Inc., a privately held ophthalmic medical device company, and Senior Vice President of Sales and Marketing at STAAR Surgical Company. In 1996, he founded Refractive Surgical Resources, a pioneering company in transportable surgical services, which was subsequently acquired by Laser Vision Centers, Inc. in 1998. He has extensive experience in product development, commercialization, and mergers and acquisitions.

Thomas R. Staab, II Chief Financial Officer and Secretary

Thomas R. Staab, II joined LENSAR as Chief Financial Officer in May 2020. He is a Certified Public Accountant with significant experience in the biopharmaceutical sector. Prior to LENSAR, Mr. Staab was Senior Vice President, Chief Financial Officer, and Treasurer at BioCryst Pharmaceuticals, Inc. from July 2011 to February 2020. He also served as Executive Vice President, Chief Financial Officer, and Treasurer of Inspire Pharmaceuticals from May 2003 until its acquisition by Merck & Co., Inc. in May 2011, and as acting Chief Financial Officer and Treasurer at Triangle Pharmaceuticals, Inc. through its acquisition by Gilead Sciences, Inc. in 2003. Before entering the biopharmaceutical industry, Mr. Staab spent eight years providing audit and business advisory services at PricewaterhouseCoopers LLP.

Alan B. Connaughton Chief Operating Officer

Alan B. Connaughton has held the position of Chief Operating Officer at LENSAR since April 2015. Before this role, he served as the Vice President of Operations from January 2008 to April 2015. Mr. Connaughton brings over 20 years of experience from various medical device companies to his role.

AI Analysis | Feedback

The key risks to LENSAR, Inc. (LNSR) are primarily centered around its recent terminated merger, its specialized product focus within a highly competitive market, and its ongoing financial stability.

  1. Risks Related to the Terminated Merger with Alcon: LENSAR recently terminated its merger agreement with Alcon due to regulatory concerns. This event introduces significant risks, including potential substantial costs, expenses, and fees associated with the termination that may not be fully covered by the $10 million deposit retained from Alcon. The company also faces the risk of potential litigation related to the terminated merger. Furthermore, the termination could adversely affect LENSAR's relationships with customers, suppliers, and other business partners, and its ability to retain and hire key personnel, disrupting management's focus from ongoing business operations. There is also increased uncertainty regarding the company's standalone strategy and its ability to grow its business and secure financing on favorable terms, or at all, following the failed acquisition.
  2. Reliance on a Single Product and Intense Competition: LENSAR operates as a specialized, small-cap company in the highly competitive ophthalmic surgery device market. Its strategic focus is primarily on a single technology: the femtosecond laser-assisted cataract surgery (FLACS) and its ALLY Adaptive Cataract Treatment System. While this specialization allows for rapid innovation, it also means the company's future heavily relies on the successful commercialization and market acceptance of this one platform. LENSAR competes against much larger, diversified healthcare corporations such as Alcon, Johnson & Johnson Vision, and Carl Zeiss Meditec, which possess significantly deeper financial resources, extensive global distribution networks, and vast product portfolios. These larger competitors can offer bundled solutions and have established brands, making it challenging for LENSAR to gain and maintain market share.
  3. Financial Stability and Ability to Obtain Future Financing: LENSAR has faced financial challenges, including negative cash flow and a history of losses. The company's financial health, as indicated by a poor Piotroski F-Score, suggests weaknesses in business operations and potential liquidity challenges. Securing sufficient funding to achieve profitability is a primary risk. The ability to obtain financing on favorable terms, or at all, is crucial for its continued operations and growth, especially in the wake of the terminated merger and as it navigates a standalone path.

AI Analysis | Feedback

null

AI Analysis | Feedback

The addressable markets for LENSAR's main products and services, which include femtosecond laser systems for the treatment of cataracts and the management of corneal astigmatism, are substantial globally.

The global ophthalmic femtosecond lasers market, which encompasses the technology central to LENSAR's offerings for cataract and refractive surgery, was valued at approximately USD 332.54 million in 2023. This market is projected to reach USD 371.7 million in 2025 and is expected to grow to USD 724.39 million by 2035, demonstrating a compound annual growth rate (CAGR) of 6.9% from 2025 to 2035. Another estimate projects this market to reach USD 347.7 million in 2025 and maintain a CAGR of 6.9% from 2025 to 2033.

For the management of pre-existing or surgically induced corneal astigmatism, a key application of LENSAR's technology, the global astigmatism market was valued at approximately USD 2.69 billion in 2022. This market is anticipated to reach USD 5.8 billion by 2032, with a CAGR of 8.12% during the forecast period from 2023 to 2032. Another report estimates the global astigmatism market size in 2023 to be approximately USD 4.5 billion, with a projected CAGR of 5.8% from 2024 to 2032, reaching USD 7.8 billion by 2032. North America holds a significant share of the astigmatism market, accounting for 43.20%. The Asia Pacific region is also expected to experience high growth in the astigmatism market, with a projected CAGR of 7.0%.

AI Analysis | Feedback

LENSAR, Inc. (LNSR) anticipates several key drivers for its future revenue growth over the next 2-3 years, primarily centered around the continued adoption and expansion of its ALLY Robotic Cataract Laser System. These drivers are identified despite the recent termination of the merger agreement with Alcon, which refocuses LENSAR on its standalone growth strategy.

  1. Increased ALLY System Placements: A significant driver of revenue growth is the continued placement of LENSAR's ALLY Systems. The company has consistently reported strong system placement activity, with a notable increase in its installed base both in the U.S. and internationally. For example, LENSAR placed 14 ALLY Systems in Q1 2025, a 40% increase over Q1 2024, and reported an additional backlog of 24 systems awaiting installation as of March 31, 2025. This expansion directly contributes to both immediate system sales revenue and a growing foundation for recurring revenue.
  2. Growth in ALLY Procedure Volumes and Recurring Revenue: As the installed base of ALLY Systems expands, a corresponding increase in procedure volumes is expected. LENSAR has emphasized that the utilization of newly placed systems ramps up over time, leading to higher recurring revenue from associated consumables and services. Worldwide procedure volumes increased by approximately 11% in Q3 2025 compared to 2024, and U.S. procedures saw a 22% year-over-year increase in Q3 2024. The company expects this trend to continue, especially as users new to LENSAR convert to ALLY from older competing lasers.
  3. International Market Expansion: LENSAR has demonstrated success in expanding its market presence beyond the United States. Recent reports highlight strong growth driven by expansion into new international markets, such as the European Union and Taiwan, which have contributed to increased system sales and overall revenue. The company’s strategy involves broadening the adoption of its femtosecond laser-assisted cataract surgery (FLACS) technology globally.
  4. Market Share Gains and Competitive Conversions: LENSAR is actively focused on gaining market share by converting competitive systems and targeting "femto-naive" accounts (those new to femtosecond laser-assisted cataract surgery). By strategically expanding its commercial team, LENSAR aims to accelerate these market share gains and ALLY placement successes, leveraging the platform's ability to drive better surgeon efficiency and deliver improved patient outcomes.

AI Analysis | Feedback

Share Repurchases

No significant share repurchases were identified during the last 3-5 years.

Share Issuance

  • Between December 31, 2024, and September 30, 2025, LENSAR's common stock issued and outstanding increased from 11,654 thousand shares to 11,935 thousand shares. This corresponds to an increase in additional paid-in capital of approximately $2.051 million during this period (from $148,035 thousand to $150,086 thousand).
  • During the first quarter of 2025, the number of issued and outstanding shares increased by 136 thousand to 11,790 thousand shares as of March 31, 2025, from 11,654 thousand shares at December 31, 2024. This contributed to an increase in additional paid-in capital by approximately $0.343 million during Q1 2025.
  • Shares were withheld from executives, such as the COO and CEO in early 2026, to cover tax obligations arising from the vesting of restricted stock units (RSUs), indicating share issuance related to compensation. For example, the CFO had 1,826 shares withheld at $11.57 per share on January 11, 2026, for tax obligations after an RSU vesting event.

Inbound Investments

  • In March 2025, Alcon Inc. entered into a definitive merger agreement to acquire LENSAR, Inc. for approximately $430 million. The deal terms include $14.00 per share in cash, with a non-tradeable contingent value right of up to $2.75 per share, dependent on achieving 614,000 cumulative procedures with LENSAR's products by December 31, 2027.
  • LENSAR received a $10.0 million cash deposit in the first quarter of 2025 in connection with the proposed acquisition by Alcon.

Outbound Investments

No significant outbound investments made by LENSAR were identified during the last 3-5 years.

Capital Expenditures

  • LENSAR operates as a medical device company that designs, develops, and markets femtosecond laser systems like the ALLY Robotic Cataract Laser System. While specific capital expenditure figures were not explicitly detailed, the company's operations inherently involve ongoing investment in manufacturing and developing these advanced laser systems.
  • The company's focus on expanding the installed base of its ALLY systems, with 185 ALLY systems installed as of September 30, 2025, and a combined installed base of 425 LENSAR Laser Systems and ALLY Systems by the same date, suggests continuous investment in its product offerings and manufacturing capabilities.
  • Research and development expenses, which contribute to the creation of future assets, were $1.4 million for Q3 2025, $1.2 million for Q3 2024, $1.5 million for Q1 2025, and $1.4 million for Q1 2024.

Better Bets vs. LENSAR (LNSR)

Peer Outperformance in Life Sciences Tools & Services

LNSR has outperformed 75% of its 108 Life Sciences Tools & Services peers over 5Y. Among the peers that beat it is MEDP. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that LNSR has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
29%
of 124 industry peers · -50.5% return
3Y
86%
of 113 industry peers · 138.5% return
5Y
75%
of 108 industry peers · -31.2% return
Life Sciences Tools & Services peers with revenue growth within 4pp of LNSR's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
Ticker Name Rev Growth 3Y Avg P/E 1Y3Y5Y 5Y Gap
LNSR LENSAR 14.6% 1.8x -50.5%138.5%-31.2% —
MEDP Medpace 16.8% 35.3x 10.8%132.3%198.9% +230pp
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is LNSR's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 6 10.3%56.1%108.0% CAH 517% · MCK 409% · COR 206%
Health Care Services 20 30.9%20.9%12.5% RDNT 145% · HIMS 141% · DGX 95%
Managed Health Care 8 72.3%-2.6%2.7% OSCR 155% · HQY 54% · HUM 8%
Health Care Facilities 26 18.0%25.0%-6.7% THC 257% · NHC 227% · EHC 196%
Health Care Equipment 50 7.8%11.1%-15.2% GKOS 401% · UFPT 346% · TMDX 255%
Pharmaceuticals 60 -15.0%7.7%-39.5% LQDA 1081% · KNSA 639% · XERS 572%
Health Care Supplies 11 26.2%6.1%-39.8% LNTH 241% · HAE 112% · MMSI 27%
Life Sciences Tools & Services ← 109 -15.3%-17.9%-74.4% AXGN 378% · MEDP 199% · NTRA 175%
Biotechnology 365 -26.3%-32.0%-81.4% ELVN 1259% · TRVI 1141% · DNTH 1129%
Health Care Technology 22 -20.8%-57.2%-82.3% VEEV -4% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Title
0ARTICLES

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

LNSRJNJBLCOMedian
NameLENSAR Johnson .Bausch &. 
Mkt Price5.25289.0521.0921.09
Mkt Cap0.1696.57.57.5
Rev LTM6099,3355,4185,418
Op Inc LTM-225,525510510
FCF LTM-519,595252252
FCF 3Y Avg-819,100-1-1
CFO LTM-526,159554554
CFO 3Y Avg-825,170316316

Growth & Margins

LNSRJNJBLCOMedian
NameLENSAR Johnson .Bausch &. 
Rev Chg LTM1.6%7.8%8.9%7.8%
Rev Chg 3Y Avg14.6%5.9%11.0%11.0%
Rev Chg Q-1.3%5.9%7.3%5.9%
QoQ Delta Rev Chg LTM-0.3%1.4%1.8%1.4%
Op Inc Chg LTM90.6%7.9%339.7%90.6%
Op Inc Chg 3Y Avg-8.4%4.4%100.0%4.4%
Op Mgn LTM-3.3%25.7%9.4%9.4%
Op Mgn 3Y Avg-18.8%25.4%5.3%5.3%
QoQ Delta Op Mgn LTM10.2%-1.1%1.8%1.8%
CFO/Rev LTM-7.7%26.3%10.2%10.2%
CFO/Rev 3Y Avg-13.6%27.1%6.1%6.1%
FCF/Rev LTM-7.9%19.7%4.7%4.7%
FCF/Rev 3Y Avg-13.8%20.6%-0.2%-0.2%

Valuation

LNSRJNJBLCOMedian
NameLENSAR Johnson .Bausch &. 
Mkt Cap0.1696.57.57.5
P/S1.17.01.41.4
P/Op Inc-32.927.314.814.8
P/EBIT-32.937.219.919.9
P/E1.943.3-67.91.9
P/CFO-14.026.613.613.6
Total Yield54.3%4.2%-1.5%4.2%
Dividend Yield0.0%1.8%0.0%0.0%
FCF Yield 3Y Avg-8.7%4.0%-0.1%-0.1%
D/E0.00.10.70.1
Net D/E-0.20.00.60.0

Returns

LNSRJNJBLCOMedian
NameLENSAR Johnson .Bausch &. 
1M Rtn-9.5%13.1%27.9%13.1%
3M Rtn-36.0%11.6%23.7%11.6%
6M Rtn-5.2%28.9%31.1%28.9%
12M Rtn-48.1%50.9%35.2%35.2%
3Y Rtn150.5%109.7%34.5%109.7%
1M Excs Rtn-11.2%15.8%28.2%15.8%
3M Excs Rtn-33.4%12.4%25.7%12.4%
6M Excs Rtn-8.2%26.0%28.2%26.0%
12M Excs Rtn-61.3%40.7%15.8%15.8%
3Y Excs Rtn83.7%34.7%-46.0%34.7%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Single Segment585342  
Lease   65
Product   2626
Service   33
Total5853423534


Net Income by Segment
$ Mil20252024
Single Segment-34-31
Total-34-31


Price Behavior

Price Behavior
Market Price$5.00 
Market Cap ($ Bil)0.1 
First Trading Date10/02/2020 
Distance from 52W High-60.7% 
   50 Days200 Days
DMA Price$6.43$7.10
DMA Trenddowndown
Distance from DMA-22.3%-29.6%
 3M1YR
Volatility54.5%68.9%
Downside Capture229.93129.74
Upside Capture-46.7018.62
Correlation (S&P 500)21.0%13.4%
LNSR Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta0.150.101.600.580.610.53
Up Beta0.530.282.140.800.770.54
Down Beta0.04-0.010.640.760.540.35
Up Capture-85%-106%209%38%2%44%
Bmk +ve Days12182862130427
Stock +ve Days7162853116373
Down Capture99%166%112%42%103%72%
Bmk -ve Days10253664121325
Stock -ve Days15273669127356

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with LNSR
LNSR-52.1%68.9%-0.77-
Sector ETF (XLV)25.8%16.8%1.1815.6%
Equity (SPY)11.6%13.7%0.5413.4%
Gold (GLD)-7.9%28.9%-0.297.9%
Commodities (DBC)33.8%21.3%1.26-10.8%
Real Estate (VNQ)10.7%14.2%0.4714.7%
Bitcoin (BTCUSD)-33.0%43.7%-0.798.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with LNSR
LNSR-6.8%66.5%0.17-
Sector ETF (XLV)9.1%15.4%0.3910.5%
Equity (SPY)11.5%17.3%0.4912.4%
Gold (GLD)15.9%19.2%0.662.7%
Commodities (DBC)7.8%19.6%0.28-1.0%
Real Estate (VNQ)1.3%18.9%-0.0412.6%
Bitcoin (BTCUSD)2.2%51.6%0.2310.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with LNSR
LNSR-5.5%68.0%0.15-
Sector ETF (XLV)13.0%16.8%0.649.7%
Equity (SPY)15.5%18.0%0.7312.2%
Gold (GLD)11.1%16.6%0.542.3%
Commodities (DBC)7.6%18.1%0.331.4%
Real Estate (VNQ)6.3%20.7%0.2612.7%
Bitcoin (BTCUSD)58.4%66.2%0.987.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity0.3 Mil
Short Interest: % Change Since 10152026-0.2%
Average Daily Volume0.0 Mil
Days-to-Cover Short Interest6.8 days
Basic Shares Quantity12.4 Mil
Short % of Basic Shares2.5%

Earnings Returns History

Updated 11/13/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/10/2026-15.4%  
8/13/202631.5%38.6%20.8%
5/8/20267.8%11.5%7.1%
11/6/2025-8.6%-16.9%-10.6%
8/7/2025-1.5%-2.1%-6.6%
5/8/2025-0.1%2.5%-5.2%
2/27/202514.8%62.0%49.3%
11/7/202417.2%26.1%31.4%
...
SUMMARY STATS   
# Positive141411
# Negative10912
Median Positive8.2%5.7%20.8%
Median Negative-5.0%-3.6%-11.2%
Max Positive31.5%62.0%57.3%
Max Negative-15.4%-30.5%-28.4%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/10/2026-15.4%  
8/13/202631.5%38.6%20.8%
5/8/20267.8%11.5%7.1%
11/6/2025-8.6%-16.9%-10.6%
8/7/2025-1.5%-2.1%-6.6%
5/8/2025-0.1%2.5%-5.2%
2/27/202514.8%62.0%49.3%
11/7/202417.2%26.1%31.4%
8/8/2024-9.9%-9.5%2.3%
5/9/202412.7%22.4%36.0%
3/4/20242.8%-13.0%-26.8%
11/9/202312.4%5.0%12.4%
8/9/202312.7%6.1%-3.6%
5/15/2023-9.4%-1.2%57.3%
3/16/20232.2%-30.5%-16.0%
11/9/2022-11.6%-3.1%-28.4%
8/8/20220.9%-1.7%-19.4%
5/9/2022-1.0%-3.6%-11.8%
3/3/20226.3%5.3%26.7%
11/8/2021-0.7%1.2%-4.1%
8/5/20211.3%4.9%1.3%
5/5/2021-0.8%12.4%17.5%
3/10/20215.6%2.3%-15.8%
11/9/20208.6%5.1%-1.5%
SUMMARY STATS   
# Positive141411
# Negative10912
Median Positive8.2%5.7%20.8%
Median Negative-5.0%-3.6%-11.2%
Max Positive31.5%62.0%57.3%
Max Negative-15.4%-30.5%-28.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/10/202610-Q
06/30/202608/13/202610-Q
03/31/202605/08/202610-Q
12/31/202503/31/202610-K
09/30/202511/06/202510-Q
06/30/202508/07/202510-Q
03/31/202505/08/202510-Q
12/31/202402/27/202510-K
09/30/202411/07/202410-Q
06/30/202408/08/202410-Q
03/31/202405/09/202410-Q
12/31/202303/04/202410-K
09/30/202311/09/202310-Q
06/30/202308/09/202310-Q
03/31/202305/15/202310-Q
12/31/202203/16/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/10/202610-Q
06/30/202608/13/202610-Q
03/31/202605/08/202610-Q
12/31/202503/31/202610-K
09/30/202511/06/202510-Q
06/30/202508/07/202510-Q
03/31/202505/08/202510-Q
12/31/202402/27/202510-K
09/30/202411/07/202410-Q
06/30/202408/08/202410-Q
03/31/202405/09/202410-Q
12/31/202303/04/202410-K
09/30/202311/09/202310-Q
06/30/202308/09/202310-Q
03/31/202305/15/202310-Q
12/31/202203/16/202310-K
09/30/202211/09/202210-Q
06/30/202208/08/202210-Q
03/31/202205/09/202210-Q
12/31/202103/03/202210-K
09/30/202111/08/202110-Q
06/30/202108/06/202110-Q
03/31/202105/06/202110-Q
12/31/202003/12/202110-K
09/30/202011/12/202010-Q
Core Cache Last Updated: 11/15/2026